tradingkey.logo

Transmedics Group Inc

TMDX

118.590USD

+4.300+3.76%
Market hours ETQuotes delayed by 15 min
4.04BMarket Cap
56.33P/E TTM

Transmedics Group Inc

118.590

+4.300+3.76%
More Details of Transmedics Group Inc Company
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
Ticker SymbolTMDX
Company nameTransmedics Group Inc
IPO dateMay 02, 2019
CEODr. Waleed H. Hassanein, M.D.
Number of employees728
Security typeOrdinary Share
Fiscal year-endMay 02
Address200 Minuteman Road
CityANDOVER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01810
Phone19785520900
Websitehttps://www.transmedics.com/
Ticker SymbolTMDX
IPO dateMay 02, 2019
CEODr. Waleed H. Hassanein, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
+13.06%
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+110.86%
Mr. Anil Ranganath
Mr. Anil Ranganath
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
1.87K
-87.03%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-97.93%
Mr. Edwin M. Kania, Jr.
Mr. Edwin M. Kania, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
+13.06%
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
108.86M
76.29%
OCS Heart net revenue
29.82M
20.90%
OCS Lung net revenue
4.01M
2.81%
By RegionUSD
Name
Revenue
Proportion
United States
138.62M
97.15%
All other countries
4.07M
2.85%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
108.86M
76.29%
OCS Heart net revenue
29.82M
20.90%
OCS Lung net revenue
4.01M
2.81%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.87%
Fidelity Management & Research Company LLC
13.57%
The Vanguard Group, Inc.
10.53%
State Street Global Advisors (US)
3.78%
Macquarie Investment Management
2.79%
Other
55.46%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.87%
Fidelity Management & Research Company LLC
13.57%
The Vanguard Group, Inc.
10.53%
State Street Global Advisors (US)
3.78%
Macquarie Investment Management
2.79%
Other
55.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor
74.77%
Investment Advisor/Hedge Fund
21.86%
Hedge Fund
6.13%
Research Firm
5.08%
Individual Investor
3.01%
Pension Fund
1.70%
Bank and Trust
1.65%
Sovereign Wealth Fund
0.15%
Family Office
0.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
746
42.27M
124.01%
-2.30M
2025Q1
751
42.32M
125.08%
-2.32M
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
2023Q2
462
35.43M
108.88%
-81.81K
2023Q1
431
32.52M
99.99%
-2.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.83M
14.26%
-61.18K
-1.25%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.66M
13.77%
+708.11K
+17.92%
Mar 31, 2025
The Vanguard Group, Inc.
3.57M
10.54%
-60.92K
-1.68%
Mar 31, 2025
State Street Global Advisors (US)
1.31M
3.86%
-54.72K
-4.02%
Mar 31, 2025
Macquarie Investment Management
1.12M
3.3%
+123.10K
+12.40%
Mar 31, 2025
Fidelity International
985.22K
2.91%
+129.87K
+15.18%
Mar 31, 2025
Driehaus Capital Management, LLC
778.75K
2.3%
+17.91K
+2.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
793.41K
2.35%
+20.66K
+2.67%
Mar 31, 2025
Emerald Advisers LLC
717.37K
2.12%
+126.38K
+21.38%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Fidelity Sustainable US Equity ETF
0.97%
BNY Mellon Innovators ETF
0.94%
OneAscent Small Cap Core ETF
0.47%
iShares ESG Select Screened S&P Small-Cap ETF
0.32%
BNY Mellon US Small Cap Core Equity ETF
0.2%
ProShares UltraPro Russell2000
0.15%
Proshares Ultra Russell 2000
0.15%
Timothy Plan US Small Cap Core ETF
0.14%
First Trust Multicap Growth Alphadex Fund
0.09%
iShares Morningstar Small-Cap ETF
0.07%
View more
Fidelity Sustainable US Equity ETF
Proportion0.97%
BNY Mellon Innovators ETF
Proportion0.94%
OneAscent Small Cap Core ETF
Proportion0.47%
iShares ESG Select Screened S&P Small-Cap ETF
Proportion0.32%
BNY Mellon US Small Cap Core Equity ETF
Proportion0.2%
ProShares UltraPro Russell2000
Proportion0.15%
Proshares Ultra Russell 2000
Proportion0.15%
Timothy Plan US Small Cap Core ETF
Proportion0.14%
First Trust Multicap Growth Alphadex Fund
Proportion0.09%
iShares Morningstar Small-Cap ETF
Proportion0.07%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI